Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and Fran...
T. Aurran-Schleinitz, R. Letestu, M. Sartor et al.· British Journal of Haematolo...· 0 citations
BACKGROUND
Despite pre-emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients.
AIMS AND METHODS
To understand the state of practice...
Andrea S. Henden, L. Chee, Julia E. Clark et al.· Internal medicine journal (P...· 0 citations
A 21-parameter spectral cytometry antibody panel is developed to characterise peripheral blood mononuclear cells from adult allogeneic HSCT-recipients at four timepoints over the course of HCMV reactivation, including before and at initial detection of HCMV DNAemia.
Danya Kaplan, E. Blyth, Selmir Avdic et al.· Blood· 0 citations
A multiplex prime-editing platform is developed that converts commonly used immunosuppressive drugs into tools for in vivo control of T-cell therapies via defined, pathway-specific drug resistance, enabling selective in vivo modulation in settings where immunosuppression cannot be withdrawn.
E. Bandala-Sanchez, Emma V. Petley, K. Ramsay et al.· Blood· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
